Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,inventory,accountsPayable,longTermDebt,otherCurrentAssets,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,market,currency,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,marketState,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,maxAge,address1,fax,industry,address2
t0,IYXI,-57632000.0,0,667000,,-9743000,,-9743000,9430000,7413000,-4735000,-4735000,,-2708000,,,,0,18006000,22741000,10593000,-5008000,,-9743000,-9743000,18769000.0,43479000.0,153357000.0,-38863000.0,4718000.0,7813000.0,114494000.0,52000.0,-83523000.0,1129000.0,14510000.0,1518000.0,153357000.0,49366000.0,1129000.0,41528000.0,39687000.0,22790000.0,12117000.0,13966000.0,,,-5603000.0,-1028000.0,-13103000.0,19660000.0,22679000.0,4769000.0,3019000.0,174000.0,-523000.0,-8879000.0,2051000.0,-2709000.0,-4936000.0,2522000.0,-3067000.0,,-113670000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,-0.9350144,0,PRE,PNK,False,False,0.0002,1630503024,0.0,0.0002,0.0002,0.0002,1000,-0.00027027025,15,America/New_York,EDT,4,0.0,2.0E-4 - 2.0E-4,0.0002,0.0,0.0,0,0,finmb_7683082,Other OTC,"Inyx, Inc.",USD,165157,0,0.0,0.0,2.0E-4 - 0.0124,-0.012200001,-0.983871,0.0002,0.0124,-0.789,-14400000,-0.74,0.005851143,-0.005651143,-0.96581864,0.0030776055,-0.0028776056,727,INYX INC,0.54,,,0.0124,0.0002,0.0059,0.0031,165.16k,,,,,0.00%,0.63%,,,,,,,,,,,,,,5:1,"Mar 04, 2003","Dec 30, 2005","Sep 29, 2006",-43.66%,-23.07%,-11.73%,,85.04M,1.81,39.50%,14.71M,-11.43M,-36.21M,-0.7890,,1.52M,0.03,119.36M,,0.26,-0.74,-22.93M,-9.7M,Value,10022,,572,"Inyx, Inc., through its wholly-owned subsidiaries, operates as a specialty pharmaceutical company in the United States, Canada, and Europe. It develops and manufactures prescription and over-the-counter pharmaceutical products. The company manufactures hydrocarbon aerosols, a delivery system for dermatological and topical drug applications; metered dose inhalers that are used for respiratory conditions; dry powdered inhalers used for respiratory ailments; metered dose nasal and throat pumps, and sprays; and sterile salines and injectables. It focuses on research and development activities on inhalation-therapy drug delivery devices and inhalation methods, and generic prescription, and over-the-counter aerosol pharmaceutical products for respiratory, allergy, dermatological, and topical and cardiovascular applications. The company's proprietary products under development include generic versions of nonchlorofluorocarbon or hydrofluoroalkane single molecule and combination drug respiratory inhalants, nonCFC propelled oral sprays for cardiovascular ailments, wound irrigation, and cleansing sprays that utilize novel barrier technologies, and anti-inflammatory nasal pumps. It also provides specialty pharmaceutical development and manufacturing consulting services to the international healthcare market. The company was incorporated in 2000 and is based in New York, New York.",New York,212-838-1111,NY,1135987200,United States,86400,825 Third Avenue,212-838-0060,,40th Floor
t-1,IYXI,-48108000.0,0,485000,,-9845000,,-9845000,10863000,7614000,-5715000,-5715000,,-2430000,,,,0,20142000,25857000,12528000,-4130000,,-9845000,-9845000,14534000.0,40152000.0,134117000.0,-33574000.0,5383000.0,5509000.0,100543000.0,50000.0,-73781000.0,5000.0,6835000.0,1344000.0,92357000.0,9350000.0,5000.0,41440000.0,37734000.0,23189000.0,9790000.0,14368000.0,41760000.0,,-5603000.0,5920000.0,-3421000.0,3634000.0,5433000.0,-1521000.0,1786000.0,-244000.0,1568000.0,-3824000.0,1981000.0,559000.0,-1752000.0,662000.0,-1074000.0,13000.0,-54623000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,-0.9350144,0,PRE,PNK,False,False,0.0002,1630503024,0.0,0.0002,0.0002,0.0002,1000,-0.00027027025,15,America/New_York,EDT,4,0.0,2.0E-4 - 2.0E-4,0.0002,0.0,0.0,0,0,finmb_7683082,Other OTC,"Inyx, Inc.",USD,165157,0,0.0,0.0,2.0E-4 - 0.0124,-0.012200001,-0.983871,0.0002,0.0124,-0.789,-14400000,-0.74,0.005851143,-0.005651143,-0.96581864,0.0030776055,-0.0028776056,727,INYX INC,0.54,,,0.0124,0.0002,0.0059,0.0031,165.16k,,,,,0.00%,0.63%,,,,,,,,,,,,,,5:1,"Mar 04, 2003","Dec 30, 2005","Sep 29, 2006",-43.66%,-23.07%,-11.73%,,85.04M,1.81,39.50%,14.71M,-11.43M,-36.21M,-0.7890,,1.52M,0.03,119.36M,,0.26,-0.74,-22.93M,-9.7M,Value,10022,,572,"Inyx, Inc., through its wholly-owned subsidiaries, operates as a specialty pharmaceutical company in the United States, Canada, and Europe. It develops and manufactures prescription and over-the-counter pharmaceutical products. The company manufactures hydrocarbon aerosols, a delivery system for dermatological and topical drug applications; metered dose inhalers that are used for respiratory conditions; dry powdered inhalers used for respiratory ailments; metered dose nasal and throat pumps, and sprays; and sterile salines and injectables. It focuses on research and development activities on inhalation-therapy drug delivery devices and inhalation methods, and generic prescription, and over-the-counter aerosol pharmaceutical products for respiratory, allergy, dermatological, and topical and cardiovascular applications. The company's proprietary products under development include generic versions of nonchlorofluorocarbon or hydrofluoroalkane single molecule and combination drug respiratory inhalants, nonCFC propelled oral sprays for cardiovascular ailments, wound irrigation, and cleansing sprays that utilize novel barrier technologies, and anti-inflammatory nasal pumps. It also provides specialty pharmaceutical development and manufacturing consulting services to the international healthcare market. The company was incorporated in 2000 and is based in New York, New York.",New York,212-838-1111,NY,1135987200,United States,86400,825 Third Avenue,212-838-0060,,40th Floor
t-2,IYXI,-42588000.0,0,682000,,-2593000,,-2593000,5972000,8301000,-303000,-303000,,-2290000,,,,0,21412000,21715000,13111000,-2290000,,-2593000,-2593000,14817000.0,38070000.0,125236000.0,-27771000.0,4192000.0,1885000.0,97465000.0,48000.0,-63936000.0,-1953000.0,5733000.0,1588000.0,81051000.0,9255000.0,-1953000.0,39184000.0,37731000.0,22450000.0,10974000.0,14523000.0,44185000.0,,-5603000.0,3995000.0,-3845000.0,-1123000.0,3446000.0,-683000.0,4582000.0,565000.0,377000.0,587000.0,1950000.0,63000.0,-1960000.0,-345000.0,-1158000.0,-13000.0,-43320000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,-0.9350144,0,PRE,PNK,False,False,0.0002,1630503024,0.0,0.0002,0.0002,0.0002,1000,-0.00027027025,15,America/New_York,EDT,4,0.0,2.0E-4 - 2.0E-4,0.0002,0.0,0.0,0,0,finmb_7683082,Other OTC,"Inyx, Inc.",USD,165157,0,0.0,0.0,2.0E-4 - 0.0124,-0.012200001,-0.983871,0.0002,0.0124,-0.789,-14400000,-0.74,0.005851143,-0.005651143,-0.96581864,0.0030776055,-0.0028776056,727,INYX INC,0.54,,,0.0124,0.0002,0.0059,0.0031,165.16k,,,,,0.00%,0.63%,,,,,,,,,,,,,,5:1,"Mar 04, 2003","Dec 30, 2005","Sep 29, 2006",-43.66%,-23.07%,-11.73%,,85.04M,1.81,39.50%,14.71M,-11.43M,-36.21M,-0.7890,,1.52M,0.03,119.36M,,0.26,-0.74,-22.93M,-9.7M,Value,10022,,572,"Inyx, Inc., through its wholly-owned subsidiaries, operates as a specialty pharmaceutical company in the United States, Canada, and Europe. It develops and manufactures prescription and over-the-counter pharmaceutical products. The company manufactures hydrocarbon aerosols, a delivery system for dermatological and topical drug applications; metered dose inhalers that are used for respiratory conditions; dry powdered inhalers used for respiratory ailments; metered dose nasal and throat pumps, and sprays; and sterile salines and injectables. It focuses on research and development activities on inhalation-therapy drug delivery devices and inhalation methods, and generic prescription, and over-the-counter aerosol pharmaceutical products for respiratory, allergy, dermatological, and topical and cardiovascular applications. The company's proprietary products under development include generic versions of nonchlorofluorocarbon or hydrofluoroalkane single molecule and combination drug respiratory inhalants, nonCFC propelled oral sprays for cardiovascular ailments, wound irrigation, and cleansing sprays that utilize novel barrier technologies, and anti-inflammatory nasal pumps. It also provides specialty pharmaceutical development and manufacturing consulting services to the international healthcare market. The company was incorporated in 2000 and is based in New York, New York.",New York,212-838-1111,NY,1135987200,United States,86400,825 Third Avenue,212-838-0060,,40th Floor
t-3,IYXI,-45182000.0,0,1530000,,-14029000,,-14946000,14286000,6856000,-11166000,-11166000,,-2163000,,,,0,25479000,36645000,18623000,-2863000,,-14029000,-14946000,14782000.0,33315000.0,122553000.0,-30400000.0,1841000.0,2058000.0,92153000.0,43000.0,-61343000.0,-2415000.0,3406000.0,1023000.0,76317000.0,9288000.0,-2415000.0,39240000.0,34725000.0,20137000.0,11331000.0,11589000.0,46236000.0,67000.0,-5603000.0,-2205000.0,47937000.0,-44631000.0,-41459000.0,6046000.0,3342000.0,-3197000.0,-2302000.0,-7373000.0,2206000.0,4721000.0,-7398000.0,4190000.0,-1213000.0,-170000.0,-41592000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,-0.9350144,0,PRE,PNK,False,False,0.0002,1630503024,0.0,0.0002,0.0002,0.0002,1000,-0.00027027025,15,America/New_York,EDT,4,0.0,2.0E-4 - 2.0E-4,0.0002,0.0,0.0,0,0,finmb_7683082,Other OTC,"Inyx, Inc.",USD,165157,0,0.0,0.0,2.0E-4 - 0.0124,-0.012200001,-0.983871,0.0002,0.0124,-0.789,-14400000,-0.74,0.005851143,-0.005651143,-0.96581864,0.0030776055,-0.0028776056,727,INYX INC,0.54,,,0.0124,0.0002,0.0059,0.0031,165.16k,,,,,0.00%,0.63%,,,,,,,,,,,,,,5:1,"Mar 04, 2003","Dec 30, 2005","Sep 29, 2006",-43.66%,-23.07%,-11.73%,,85.04M,1.81,39.50%,14.71M,-11.43M,-36.21M,-0.7890,,1.52M,0.03,119.36M,,0.26,-0.74,-22.93M,-9.7M,Value,10022,,572,"Inyx, Inc., through its wholly-owned subsidiaries, operates as a specialty pharmaceutical company in the United States, Canada, and Europe. It develops and manufactures prescription and over-the-counter pharmaceutical products. The company manufactures hydrocarbon aerosols, a delivery system for dermatological and topical drug applications; metered dose inhalers that are used for respiratory conditions; dry powdered inhalers used for respiratory ailments; metered dose nasal and throat pumps, and sprays; and sterile salines and injectables. It focuses on research and development activities on inhalation-therapy drug delivery devices and inhalation methods, and generic prescription, and over-the-counter aerosol pharmaceutical products for respiratory, allergy, dermatological, and topical and cardiovascular applications. The company's proprietary products under development include generic versions of nonchlorofluorocarbon or hydrofluoroalkane single molecule and combination drug respiratory inhalants, nonCFC propelled oral sprays for cardiovascular ailments, wound irrigation, and cleansing sprays that utilize novel barrier technologies, and anti-inflammatory nasal pumps. It also provides specialty pharmaceutical development and manufacturing consulting services to the international healthcare market. The company was incorporated in 2000 and is based in New York, New York.",New York,212-838-1111,NY,1135987200,United States,86400,825 Third Avenue,212-838-0060,,40th Floor
